The current work found that the downstream targets of HIF-1α activity, metabolic markers Ang2, GLUT1, LDHA, and PDK1, which equip the tumor for survival and growth under hypoxic conditions (43, 44), were also downregulated by anlotinib plus bevacizumab. This evidence concerns the gene LDHA and neoplasm.